ID   APEX1_HUMAN             Reviewed;         318 AA.
AC   P27695; Q969L5; Q99775;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   18-JUN-2025, entry version 268.
DE   RecName: Full=DNA repair nuclease/redox regulator APEX1;
DE            EC=3.1.11.2 {ECO:0000269|PubMed:11286553, ECO:0000269|PubMed:15380100, ECO:0000269|PubMed:19123919, ECO:0000269|PubMed:21762700};
DE            EC=3.1.21.- {ECO:0000269|PubMed:9804799};
DE   AltName: Full=APEX nuclease;
DE            Short=APEN;
DE   AltName: Full=Apurinic-apyrimidinic endonuclease 1;
DE            Short=AP endonuclease 1;
DE            Short=APE-1;
DE   AltName: Full=DNA-(apurinic or apyrimidinic site) endonuclease;
DE   AltName: Full=Redox factor-1;
DE            Short=REF-1;
DE   Contains:
DE     RecName: Full=DNA repair nuclease/redox regulator APEX1, mitochondrial;
GN   Name=APEX1; Synonyms=APE, APE1, APEX, APX, HAP1, REF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Melanocyte;
RX   PubMed=1719477; DOI=10.1093/nar/19.20.5519;
RA   Robson C.N., Hickson I.D.;
RT   "Isolation of cDNA clones encoding a human apurinic/apyrimidinic
RT   endonuclease that corrects DNA repair and mutagenesis defects in E. coli
RT   xth (exonuclease III) mutants.";
RL   Nucleic Acids Res. 19:5519-5523(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=1722334; DOI=10.1073/pnas.88.24.11450;
RA   Demple B., Herman T., Chen D.S.;
RT   "Cloning and expression of APE, the cDNA encoding the major human apurinic
RT   endonuclease: definition of a family of DNA repair enzymes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:11450-11454(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Bone marrow, and Leukocyte;
RX   PubMed=1627644; DOI=10.1016/0167-4781(92)90027-w;
RA   Seki S., Hatsushika M., Watanabe S., Akiyama K., Nagao K., Tsutsui K.;
RT   "cDNA cloning, sequencing, expression and possible domain structure of
RT   human APEX nuclease homologous to Escherichia coli exonuclease III.";
RL   Biochim. Biophys. Acta 1131:287-299(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 2-21.
RX   PubMed=1380454; DOI=10.1002/j.1460-2075.1992.tb05411.x;
RA   Xanthoudakis S., Miao G., Wang F., Pan Y.-C.E., Curran T.;
RT   "Redox activation of Fos-Jun DNA binding activity is mediated by a DNA
RT   repair enzyme.";
RL   EMBO J. 11:3323-3335(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Carcinoma;
RX   PubMed=1371347; DOI=10.1093/nar/20.2.370;
RA   Cheng X.B., Bunville J., Patterson T.A.;
RT   "Nucleotide sequence of a cDNA for an apurinic/apyrimidinic endonuclease
RT   from HeLa cells.";
RL   Nucleic Acids Res. 20:370-370(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Leukocyte;
RX   PubMed=1380694; DOI=10.1093/nar/20.15.4097;
RA   Zhao B., Grandy D.K., Hagerup J.M., Magenis R.E., Smith L., Chauhan B.C.,
RA   Henner W.D.;
RT   "The human gene for apurinic/apyrimidinic endonuclease (HAP1): sequence and
RT   localization to chromosome 14 band q12.";
RL   Nucleic Acids Res. 20:4097-4098(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1383925; DOI=10.1093/nar/20.17.4417;
RA   Robson C.N., Hocchauser D., Craig R., Rack K., Buckle I.D., Hickson I.D.;
RT   "Structure of the human DNA repair gene HAP1 and its localisation to
RT   chromosome 14q 11.2-12.";
RL   Nucleic Acids Res. 20:4417-4421(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8086453; DOI=10.1016/0167-4781(94)90241-0;
RA   Akiyama K., Seki S., Oshida T., Yoshida M.;
RT   "Structure, promoter analysis and chromosomal assignment of the human APEX
RT   gene.";
RL   Biochim. Biophys. Acta 1219:15-25(1994).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=9110174; DOI=10.1101/gr.7.4.353;
RA   Yu W., Andersson B., Worley K.C., Muzny D.M., Ding Y., Liu W.,
RA   Ricafrente J.Y., Wentland M.A., Lennon G., Gibbs R.A.;
RT   "Large-scale concatenation cDNA sequencing.";
RL   Genome Res. 7:353-358(1997).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-51; VAL-64 AND GLU-148.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLU-148.
RC   TISSUE=Brain, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-10, FUNCTION, INTERACTION WITH GZMA, CLEAVAGE BY
RP   GRANZYME A, IDENTIFICATION IN THE SET COMPLEX, MUTAGENESIS OF LYS-31;
RP   CYS-65 AND ASP-210, AND SUBCELLULAR LOCATION.
RX   PubMed=12524539; DOI=10.1038/ni885;
RA   Fan Z., Beresford P.J., Zhang D., Xu Z., Novina C.D., Yoshida A.,
RA   Pommier Y., Lieberman J.;
RT   "Cleaving the oxidative repair protein Ape1 enhances cell death mediated by
RT   granzyme A.";
RL   Nat. Immunol. 4:145-153(2003).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-146.
RC   TISSUE=Placenta;
RX   PubMed=1284593; DOI=10.1093/hmg/1.9.677;
RA   Harrison L., Ascione G., Menninger J.C., Ward D.C., Demple B.;
RT   "Human apurinic endonuclease gene (APE): structure and genomic mapping
RT   (chromosome 14q11.2-12).";
RL   Hum. Mol. Genet. 1:677-680(1992).
RN   [16]
RP   FUNCTION, AND MUTAGENESIS OF CYS-65; CYS-93; CYS-99; CYS-138; CYS-208;
RP   CYS-296 AND CYS-310.
RX   PubMed=8355688; DOI=10.1128/mcb.13.9.5370-5376.1993;
RA   Walker L.J., Robson C.N., Black E., Gillespie D., Hickson I.D.;
RT   "Identification of residues in the human DNA repair enzyme HAP1 (Ref-1)
RT   that are essential for redox regulation of Jun DNA binding.";
RL   Mol. Cell. Biol. 13:5370-5376(1993).
RN   [17]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=7516064; DOI=10.1093/nar/22.10.1866;
RA   Winters T.A., Henner W.D., Russell P.S., McCullough A., Jorgensen T.J.;
RT   "Removal of 3'-phosphoglycolate from DNA strand-break damage in an
RT   oligonucleotide substrate by recombinant human apurinic/apyrimidinic
RT   endonuclease 1.";
RL   Nucleic Acids Res. 22:1866-1873(1994).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH XRCC5 AND XRCC6.
RX   PubMed=8621488; DOI=10.1074/jbc.271.15.8593;
RA   Chung U., Igarashi T., Nishishita T., Iwanari H., Iwamatsu A., Suwa A.,
RA   Mimori T., Hata K., Ebisu S., Ogata E., Fujita T., Okazaki T.;
RT   "The interaction between Ku antigen and REF1 protein mediates negative gene
RT   regulation by extracellular calcium.";
RL   J. Biol. Chem. 271:8593-8598(1996).
RN   [19]
RP   FUNCTION, AND MUTAGENESIS OF ASN-212.
RX   PubMed=8932375; DOI=10.1093/nar/24.21.4217;
RA   Rothwell D.G., Hickson I.D.;
RT   "Asparagine 212 is essential for abasic site recognition by the human DNA
RT   repair endonuclease HAP1.";
RL   Nucleic Acids Res. 24:4217-4221(1996).
RN   [20]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8995436; DOI=10.1074/jbc.272.2.1302;
RA   Strauss P.R., Beard W.A., Patterson T.A., Wilson S.H.;
RT   "Substrate binding by human apurinic/apyrimidinic endonuclease indicates a
RT   Briggs-Haldane mechanism.";
RL   J. Biol. Chem. 272:1302-1307(1997).
RN   [21]
RP   FUNCTION, SUBUNIT, INTERACTION WITH TXN, AND SUBCELLULAR LOCATION.
RX   PubMed=9108029; DOI=10.1073/pnas.94.8.3633;
RA   Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J.;
RT   "AP-1 transcriptional activity is regulated by a direct association between
RT   thioredoxin and Ref-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3633-3638(1997).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH POLB.
RX   PubMed=9207062; DOI=10.1073/pnas.94.14.7166;
RA   Bennett R.A., Wilson D.M. III, Wong D., Demple B.;
RT   "Interaction of human apurinic endonuclease and DNA polymerase beta in the
RT   base excision repair pathway.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:7166-7169(1997).
RN   [23]
RP   FUNCTION, MUTAGENESIS OF ASP-283; ASP-308 AND HIS-309, AND COFACTOR.
RX   PubMed=9804799; DOI=10.1074/jbc.273.46.30360;
RA   Masuda Y., Bennett R.A., Demple B.;
RT   "Rapid dissociation of human apurinic endonuclease (Ape1) from incised DNA
RT   induced by magnesium.";
RL   J. Biol. Chem. 273:30360-30365(1998).
RN   [24]
RP   FUNCTION, INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9560228; DOI=10.1073/pnas.95.9.5061;
RA   Ramana C.V., Boldogh I., Izumi T., Mitra S.;
RT   "Activation of apurinic/apyrimidinic endonuclease in human cells by
RT   reactive oxygen species and its correlation with their adaptive response to
RT   genotoxicity of free radicals.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:5061-5066(1998).
RN   [25]
RP   FUNCTION, PHOSPHORYLATION BY CKII, AND SUBCELLULAR LOCATION.
RX   PubMed=10023679; DOI=10.1038/sj.onc.1202394;
RA   Fritz G., Kaina B.;
RT   "Phosphorylation of the DNA repair protein APE/REF-1 by CKII affects redox
RT   regulation of AP-1.";
RL   Oncogene 18:1033-1040(1999).
RN   [26]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11118054;
RA   Wei S.J., Botero A., Hirota K., Bradbury C.M., Markovina S., Laszlo A.,
RA   Spitz D.R., Goswami P.C., Yodoi J., Gius D.;
RT   "Thioredoxin nuclear translocation and interaction with redox factor-1
RT   activates the activator protein-1 transcription factor in response to
RT   ionizing radiation.";
RL   Cancer Res. 60:6688-6695(2000).
RN   [27]
RP   FUNCTION, AND PHOSPHORYLATION BY PKC.
RX   PubMed=11452037; DOI=10.1093/nar/29.14.3116;
RA   Hsieh M.M., Hegde V., Kelley M.R., Deutsch W.A.;
RT   "Activation of APE/Ref-1 redox activity is mediated by reactive oxygen
RT   species and PKC phosphorylation.";
RL   Nucleic Acids Res. 29:3116-3122(2001).
RN   [28]
RP   IDENTIFICATION IN THE SET COMPLEX.
RX   PubMed=11909973; DOI=10.1128/mcb.22.8.2810-2820.2002;
RA   Fan Z., Beresford P.J., Zhang D., Lieberman J.;
RT   "HMG2 interacts with the nucleosome assembly protein SET and is a target of
RT   the cytotoxic T-lymphocyte protease granzyme A.";
RL   Mol. Cell. Biol. 22:2810-2820(2002).
RN   [29]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=11832948; DOI=10.1038/415655a;
RA   Chou K.M., Cheng Y.C.;
RT   "An exonucleolytic activity of human apurinic/apyrimidinic endonuclease on
RT   3' mispaired DNA.";
RL   Nature 415:655-659(2002).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH HNRNPL.
RX   PubMed=11809897; DOI=10.1093/nar/30.3.823;
RA   Kuninger D.T., Izumi T., Papaconstantinou J., Mitra S.;
RT   "Human AP-endonuclease 1 and hnRNP-L interact with a nCaRE-like repressor
RT   element in the AP-endonuclease 1 promoter.";
RL   Nucleic Acids Res. 30:823-829(2002).
RN   [31]
RP   INTERACTION WITH HDAC1; HDAC2 AND HDAC3, ACETYLATION AT LYS-6 AND LYS-7,
RP   AND MUTAGENESIS OF LYS-6 AND LYS-7.
RX   PubMed=14633989; DOI=10.1093/emboj/cdg595;
RA   Bhakat K.K., Izumi T., Yang S.H., Hazra T.K., Mitra S.;
RT   "Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the
RT   parathyroid hormone gene.";
RL   EMBO J. 22:6299-6309(2003).
RN   [32]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AND MUTAGENESIS OF TYR-171.
RX   PubMed=15380100; DOI=10.1016/j.dnarep.2004.06.009;
RA   Mundle S.T., Fattal M.H., Melo L.F., Coriolan J.D., O'Regan N.E.,
RA   Strauss P.R.;
RT   "Novel role of tyrosine in catalysis by human AP endonuclease 1.";
RL   DNA Repair 3:1447-1455(2004).
RN   [33]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=15831793; DOI=10.1093/nar/gki518;
RA   Parsons J.L., Dianova I.I., Dianov G.L.;
RT   "APE1-dependent repair of DNA single-strand breaks containing 3'-end 8-
RT   oxoguanine.";
RL   Nucleic Acids Res. 33:2204-2209(2005).
RN   [34]
RP   INTERACTION WITH KPNA1 AND KPNA2, MUTAGENESIS OF LYS-6; LYS-7; GLU-12 AND
RP   ASP-13, AND SUBCELLULAR LOCATION.
RX   PubMed=15942031; DOI=10.1093/nar/gki641;
RA   Jackson E.B., Theriot C.A., Chattopadhyay R., Mitra S., Izumi T.;
RT   "Analysis of nuclear transport signals in the human apurinic/apyrimidinic
RT   endonuclease (APE1/Ref1).";
RL   Nucleic Acids Res. 33:3303-3312(2005).
RN   [35]
RP   FUNCTION.
RX   PubMed=16617147; DOI=10.1093/nar/gkl177;
RA   Chattopadhyay R., Wiederhold L., Szczesny B., Boldogh I., Hazra T.K.,
RA   Izumi T., Mitra S.;
RT   "Identification and characterization of mitochondrial abasic (AP)-
RT   endonuclease in mammalian cells.";
RL   Nucleic Acids Res. 34:2067-2076(2006).
RN   [36]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17148573; DOI=10.1242/jcs.03312;
RA   Campalans A., Amouroux R., Bravard A., Epe B., Radicella J.P.;
RT   "UVA irradiation induces relocalisation of the DNA repair protein hOGG1 to
RT   nuclear speckles.";
RL   J. Cell Sci. 120:23-32(2007).
RN   [37]
RP   S-NITROSYLATION AT CYS-65; CYS-93 AND CYS-310 IN RESPONSE TO NITRIC OXIDE,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=17403694; DOI=10.1093/nar/gkl1163;
RA   Qu J., Liu G.H., Huang B., Chen C.;
RT   "Nitric oxide controls nuclear export of APE1/Ref-1 through S-nitrosation
RT   of cysteines 93 and 310.";
RL   Nucleic Acids Res. 35:2522-2532(2007).
RN   [38]
RP   FUNCTION.
RX   PubMed=18439621; DOI=10.1016/j.jmb.2008.03.053;
RA   Berquist B.R., McNeill D.R., Wilson D.M. III;
RT   "Characterization of abasic endonuclease activity of human Ape1 on
RT   alternative substrates, as well as effects of ATP and sequence context on
RT   AP site incision.";
RL   J. Mol. Biol. 379:17-27(2008).
RN   [39]
RP   FUNCTION, INTERACTION WITH MVP AND YBX1, MUTAGENESIS OF LYS-6 AND LYS-7,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=18809583; DOI=10.1128/mcb.00244-08;
RA   Chattopadhyay R., Das S., Maiti A.K., Boldogh I., Xie J., Hazra T.K.,
RA   Kohno K., Mitra S., Bhakat K.K.;
RT   "Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated
RT   activation of the multidrug resistance gene MDR1.";
RL   Mol. Cell. Biol. 28:7066-7080(2008).
RN   [40]
RP   FUNCTION.
RX   PubMed=18179823; DOI=10.1016/j.molimm.2007.11.020;
RA   Guo Y., Chen J., Zhao T., Fan Z.;
RT   "Granzyme K degrades the redox/DNA repair enzyme Ape1 to trigger oxidative
RT   stress of target cells leading to cytotoxicity.";
RL   Mol. Immunol. 45:2225-2235(2008).
RN   [41]
RP   FUNCTION, AND MUTAGENESIS OF CYS-65; CYS-93; CYS-99; CYS-138; CYS-208;
RP   CYS-296 AND CYS-310.
RX   PubMed=18579163; DOI=10.1016/j.mrfmmm.2008.04.008;
RA   Georgiadis M.M., Luo M., Gaur R.K., Delaplane S., Li X., Kelley M.R.;
RT   "Evolution of the redox function in mammalian apurinic/apyrimidinic
RT   endonuclease.";
RL   Mutat. Res. 643:54-63(2008).
RN   [42]
RP   FUNCTION, COFACTOR, AND ENZYME MECHANISM.
RX   PubMed=19123919; DOI=10.1021/bi8016137;
RA   Mundle S.T., Delaney J.C., Essigmann J.M., Strauss P.R.;
RT   "Enzymatic mechanism of human apurinic/apyrimidinic endonuclease against a
RT   THF AP site model substrate.";
RL   Biochemistry 48:19-26(2009).
RN   [43]
RP   FUNCTION, INTERACTION WITH KRT8; NPM1; PRDX6; PRPF19; RPLP0 AND WDR77,
RP   RNA-BINDING, AND SUBCELLULAR LOCATION.
RX   PubMed=19188445; DOI=10.1128/mcb.01337-08;
RA   Vascotto C., Fantini D., Romanello M., Cesaratto L., Deganuto M.,
RA   Leonardi A., Radicella J.P., Kelley M.R., D'Ambrosio C., Scaloni A.,
RA   Quadrifoglio F., Tell G.;
RT   "APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the
RT   rRNA quality control process.";
RL   Mol. Cell. Biol. 29:1834-1854(2009).
RN   [44]
RP   INTERACTION WITH POLB.
RX   PubMed=26760506; DOI=10.18632/oncotarget.6849;
RA   Zhou T., Pan F., Cao Y., Han Y., Zhao J., Sun H., Zhou X., Wu X., He L.,
RA   Hu Z., Chen H., Shen B., Guo Z.;
RT   "R152C DNA Pol beta mutation impairs base excision repair and induces
RT   cellular transformation.";
RL   Oncotarget 7:6902-6915(2016).
RN   [45]
RP   FUNCTION, RNA-BINDING, AND MUTAGENESIS OF GLU-96 AND HIS-309.
RX   PubMed=19401441; DOI=10.1093/nar/gkp275;
RA   Barnes T., Kim W.C., Mantha A.K., Kim S.E., Izumi T., Mitra S., Lee C.H.;
RT   "Identification of apurinic/apyrimidinic endonuclease 1 (APE1) as the
RT   endoribonuclease that cleaves c-myc mRNA.";
RL   Nucleic Acids Res. 37:3946-3958(2009).
RN   [46]
RP   INTERACTION WITH MDM2, UBIQUITINATION, AND MUTAGENESIS OF LYS-24; LYS-25
RP   AND LYS-27.
RX   PubMed=19219073; DOI=10.1038/onc.2009.5;
RA   Busso C.S., Iwakuma T., Izumi T.;
RT   "Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-
RT   MDM2 signaling pathway.";
RL   Oncogene 28:1616-1625(2009).
RN   [47]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-197, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [48]
RP   INTERACTION WITH TOMM20, MUTAGENESIS OF LYS-24; LYS-25; LYS-27; LYS-31;
RP   LYS-299; ARG-301 AND LYS-303, AND SUBCELLULAR LOCATION.
RX   PubMed=20231292; DOI=10.1074/jbc.m109.069591;
RA   Li M., Zhong Z., Zhu J., Xiang D., Dai N., Cao X., Qing Y., Yang Z.,
RA   Xie J., Li Z., Baugh L., Wang G., Wang D.;
RT   "Identification and characterization of mitochondrial targeting sequence of
RT   human apurinic/apyrimidinic endonuclease 1.";
RL   J. Biol. Chem. 285:14871-14881(2010).
RN   [49]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH SIRT1 AND XRCC1, MUTAGENESIS
RP   OF LYS-6 AND LYS-7, AND SUBCELLULAR LOCATION.
RX   PubMed=19934257; DOI=10.1093/nar/gkp1039;
RA   Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I.,
RA   Kasuno K., Jung S.B., Kim C.S., Irani K.;
RT   "SIRT1 deacetylates APE1 and regulates cellular base excision repair.";
RL   Nucleic Acids Res. 38:832-845(2010).
RN   [50]
RP   FUNCTION, INTERACTION WITH NPM1, RNA-BINDING, ACETYLATION AT LYS-27;
RP   LYS-31; LYS-32 AND LYS-35, MUTAGENESIS OF LYS-24; LYS-25; LYS-27; LYS-31
RP   AND LYS-32, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20699270; DOI=10.1093/nar/gkq691;
RA   Fantini D., Vascotto C., Marasco D., D'Ambrosio C., Romanello M.,
RA   Vitagliano L., Pedone C., Poletto M., Cesaratto L., Quadrifoglio F.,
RA   Scaloni A., Radicella J.P., Tell G.;
RT   "Critical lysine residues within the overlooked N-terminal domain of human
RT   APE1 regulate its biological functions.";
RL   Nucleic Acids Res. 38:8239-8256(2010).
RN   [51]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [52]
RP   FUNCTION IN DNA DEMETHYLATION.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [53]
RP   MUTAGENESIS OF ASN-68; ASP-70; TYR-171; PHE-266; ASP-283; ASP-308 AND
RP   HIS-309, ACTIVE SITE, FUNCTION, AND COFACTOR.
RX   PubMed=21762700; DOI=10.1016/j.jmb.2011.06.050;
RA   Kim W.C., Berquist B.R., Chohan M., Uy C., Wilson D.M. III, Lee C.H.;
RT   "Characterization of the endoribonuclease active site of human
RT   apurinic/apyrimidinic endonuclease 1.";
RL   J. Mol. Biol. 411:960-971(2011).
RN   [54]
RP   FUNCTION, CATALYTIC ACTIVITY, AND COFACTOR.
RX   PubMed=24079850; DOI=10.1021/bi401218r;
RA   Schermerhorn K.M., Delaney S.;
RT   "Transient-state kinetics of apurinic/apyrimidinic (AP) endonuclease 1
RT   acting on an authentic AP site and commonly used substrate analogs: the
RT   effect of diverse metal ions and base mismatches.";
RL   Biochemistry 52:7669-7677(2013).
RN   [55]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-54, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [56]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [57]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [58] {ECO:0007744|PDB:1BIX}
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 32-318 IN COMPLEX WITH METAL IONS.
RX   PubMed=9351835; DOI=10.1093/emboj/16.21.6548;
RA   Gorman M.A., Morera S., Rothwell D.G., de La Fortelle E., Mol C.D.,
RA   Tainer J.A., Hickson I.D., Freemont P.S.;
RT   "The crystal structure of the human DNA repair endonuclease HAP1 suggests
RT   the recognition of extra-helical deoxyribose at DNA abasic sites.";
RL   EMBO J. 16:6548-6558(1997).
RN   [59] {ECO:0007744|PDB:1DE8, ECO:0007744|PDB:1DE9, ECO:0007744|PDB:1DEW}
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 40-318 IN COMPLEX WITH DNA AND
RP   METAL ION, AND DNA-BINDING.
RX   PubMed=10667800; DOI=10.1038/35000249;
RA   Mol C.D., Izumi T., Mitra S., Tainer J.A.;
RT   "DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA
RT   repair coordination.";
RL   Nature 403:451-456(2000).
RN   [60] {ECO:0007744|PDB:1E9N, ECO:0007744|PDB:1HD7}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH METAL IONS, AND
RP   COFACTOR.
RX   PubMed=11286553; DOI=10.1006/jmbi.2001.4529;
RA   Beernink P.T., Segelke B.W., Hadi M.Z., Erzberger J.P., Wilson D.M. III,
RA   Rupp B.;
RT   "Two divalent metal ions in the active site of a new crystal form of human
RT   apurinic/apyrimidinic endonuclease, Ape1: implications for the catalytic
RT   mechanism.";
RL   J. Mol. Biol. 307:1023-1034(2001).
CC   -!- FUNCTION: Multifunctional protein that plays a central role in the
CC       cellular response to oxidative stress. The two major activities of
CC       APEX1 are DNA repair and redox regulation of transcriptional factors
CC       (PubMed:11118054, PubMed:11452037, PubMed:15831793, PubMed:18439621,
CC       PubMed:18579163, PubMed:21762700, PubMed:24079850, PubMed:8355688,
CC       PubMed:9108029, PubMed:9560228). Functions as an apurinic/apyrimidinic
CC       (AP) endodeoxyribonuclease in the base excision repair (BER) pathway of
CC       DNA lesions induced by oxidative and alkylating agents. Initiates
CC       repair of AP sites in DNA by catalyzing hydrolytic incision of the
CC       phosphodiester backbone immediately adjacent to the damage, generating
CC       a single-strand break with 5'-deoxyribose phosphate and 3'-hydroxyl
CC       ends. Also incises at AP sites in the DNA strand of DNA/RNA hybrids,
CC       single-stranded DNA regions of R-loop structures, and single-stranded
CC       RNA molecules (PubMed:15380100, PubMed:16617147, PubMed:18439621,
CC       PubMed:19123919, PubMed:19188445, PubMed:19934257, PubMed:20699270,
CC       PubMed:21762700, PubMed:24079850, PubMed:8932375, PubMed:8995436,
CC       PubMed:9804799). Operates at switch sites of immunoglobulin (Ig)
CC       constant regions where it mediates Ig isotype class switch
CC       recombination. Processes AP sites induced by successive action of AICDA
CC       and UNG. Generates staggered nicks in opposite DNA strands resulting in
CC       the formation of double-strand DNA breaks that are finally resolved via
CC       non-homologous end joining repair pathway (By similarity). Has 3'-5'
CC       exodeoxyribonuclease activity on mismatched deoxyribonucleotides at the
CC       3' termini of nicked or gapped DNA molecules during short-patch BER
CC       (PubMed:11832948, PubMed:1719477). Possesses DNA 3' phosphodiesterase
CC       activity capable of removing lesions (such as phosphoglycolate and 8-
CC       oxoguanine) blocking the 3' side of DNA strand breaks (PubMed:15831793,
CC       PubMed:7516064). Also acts as an endoribonuclease involved in the
CC       control of single-stranded RNA metabolism. Plays a role in regulating
CC       MYC mRNA turnover by preferentially cleaving in between UA and CA
CC       dinucleotides of the MYC coding region determinant (CRD). In
CC       association with NMD1, plays a role in the rRNA quality control process
CC       during cell cycle progression (PubMed:19188445, PubMed:19401441,
CC       PubMed:21762700). Acts as a loading factor for POLB onto non-incised AP
CC       sites in DNA and stimulates the 5'-terminal deoxyribose 5'-phosphate
CC       (dRp) excision activity of POLB (PubMed:9207062). Exerts reversible
CC       nuclear redox activity to regulate DNA binding affinity and
CC       transcriptional activity of transcriptional factors by controlling the
CC       redox status of their DNA-binding domain, such as the FOS/JUN AP-1
CC       complex after exposure to IR (PubMed:10023679, PubMed:11118054,
CC       PubMed:11452037, PubMed:18579163, PubMed:8355688, PubMed:9108029).
CC       Involved in calcium-dependent down-regulation of parathyroid hormone
CC       (PTH) expression by binding to negative calcium response elements
CC       (nCaREs). Together with HNRNPL or the dimer XRCC5/XRCC6, associates
CC       with nCaRE, acting as an activator of transcriptional repression
CC       (PubMed:11809897, PubMed:14633989, PubMed:8621488). May also play a
CC       role in the epigenetic regulation of gene expression by participating
CC       in DNA demethylation (PubMed:21496894). Stimulates the YBX1-mediated
CC       MDR1 promoter activity, when acetylated at Lys-6 and Lys-7, leading to
CC       drug resistance (PubMed:18809583). Plays a role in protection from
CC       granzyme-mediated cellular repair leading to cell death
CC       (PubMed:18179823). Binds DNA and RNA. Associates, together with YBX1,
CC       on the MDR1 promoter. Together with NPM1, associates with rRNA
CC       (PubMed:19188445, PubMed:19401441, PubMed:20699270).
CC       {ECO:0000250|UniProtKB:P28352, ECO:0000269|PubMed:10023679,
CC       ECO:0000269|PubMed:11118054, ECO:0000269|PubMed:11452037,
CC       ECO:0000269|PubMed:11809897, ECO:0000269|PubMed:11832948,
CC       ECO:0000269|PubMed:12524539, ECO:0000269|PubMed:14633989,
CC       ECO:0000269|PubMed:15380100, ECO:0000269|PubMed:15831793,
CC       ECO:0000269|PubMed:16617147, ECO:0000269|PubMed:1719477,
CC       ECO:0000269|PubMed:18179823, ECO:0000269|PubMed:18439621,
CC       ECO:0000269|PubMed:18579163, ECO:0000269|PubMed:18809583,
CC       ECO:0000269|PubMed:19123919, ECO:0000269|PubMed:19188445,
CC       ECO:0000269|PubMed:19401441, ECO:0000269|PubMed:19934257,
CC       ECO:0000269|PubMed:20699270, ECO:0000269|PubMed:21496894,
CC       ECO:0000269|PubMed:21762700, ECO:0000269|PubMed:24079850,
CC       ECO:0000269|PubMed:7516064, ECO:0000269|PubMed:8355688,
CC       ECO:0000269|PubMed:8621488, ECO:0000269|PubMed:8932375,
CC       ECO:0000269|PubMed:8995436, ECO:0000269|PubMed:9108029,
CC       ECO:0000269|PubMed:9207062, ECO:0000269|PubMed:9560228,
CC       ECO:0000269|PubMed:9804799}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a deoxyribonucleotide-2'-deoxyribose-5'-monophosphate-DNA +
CC         H2O = a 5'-end 2'-deoxyribose-5'-monophosphate-DNA + a 3'-end 2'-
CC         deoxyribonucleotide-DNA + H(+); Xref=Rhea:RHEA:81527, Rhea:RHEA-
CC         COMP:13863, Rhea:RHEA-COMP:19699, Rhea:RHEA-COMP:19703,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:138148,
CC         ChEBI:CHEBI:231912, ChEBI:CHEBI:231913;
CC         Evidence={ECO:0000269|PubMed:15380100, ECO:0000269|PubMed:24079850,
CC         ECO:0000269|PubMed:8995436};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81528;
CC         Evidence={ECO:0000269|PubMed:19934257};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Exonucleolytic cleavage in the 3'- to 5'-direction to yield
CC         nucleoside 5'-phosphates.; EC=3.1.11.2;
CC         Evidence={ECO:0000269|PubMed:11832948};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3'-end 2'-deoxyribonucleotide-3'-phosphoglycolate-DNA + H2O
CC         = 2-phosphoglycolate + a 3'-end 2'-deoxyribonucleotide-DNA + H(+);
CC         Xref=Rhea:RHEA:81467, Rhea:RHEA-COMP:13863, Rhea:RHEA-COMP:19686,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:58033,
CC         ChEBI:CHEBI:138148, ChEBI:CHEBI:231894;
CC         Evidence={ECO:0000269|PubMed:7516064};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81468;
CC         Evidence={ECO:0000305|PubMed:7516064};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3'-end 2'-deoxyribonucleotide-8-oxoguanine-DNA + H2O = 8-
CC         oxo-dGMP + a 3'-end 2'-deoxyribonucleotide-DNA + H(+);
CC         Xref=Rhea:RHEA:81471, Rhea:RHEA-COMP:13863, Rhea:RHEA-COMP:19687,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:63224,
CC         ChEBI:CHEBI:138148, ChEBI:CHEBI:231896;
CC         Evidence={ECO:0000269|PubMed:15831793};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:81472;
CC         Evidence={ECO:0000305|PubMed:15831793};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11286553, ECO:0000269|PubMed:19123919,
CC         ECO:0000269|PubMed:21762700, ECO:0000269|PubMed:24079850,
CC         ECO:0000269|PubMed:9804799};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:11286553, ECO:0000269|PubMed:19123919,
CC         ECO:0000269|PubMed:21762700, ECO:0000269|PubMed:24079850,
CC         ECO:0000269|PubMed:9804799};
CC       Note=Probably binds two magnesium or manganese ions per subunit.
CC       {ECO:0000269|PubMed:11286553, ECO:0000269|PubMed:19123919,
CC       ECO:0000269|PubMed:21762700, ECO:0000269|PubMed:9804799};
CC   -!- ACTIVITY REGULATION: NPM1 stimulates endodeoxyribonuclease activity on
CC       double-stranded DNA with AP sites, but inhibits endoribonuclease
CC       activity on single-stranded RNA containing AP sites.
CC       {ECO:0000269|PubMed:19188445}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=100 nM for a
CC         deoxyribonucleotide-2'-deoxyribose-5'-monophosphate-DNA
CC         {ECO:0000269|PubMed:8995436};
CC   -!- SUBUNIT: Monomer. Homodimer; disulfide-linked. Component of the SET
CC       complex, composed of at least APEX1, SET, ANP32A, HMGB2, NME1 and
CC       TREX1. Associates with the dimer XRCC5/XRCC6 in a DNA-dependent manner.
CC       Interacts with SIRT1; the interaction is increased in the context of
CC       genotoxic stress. Interacts with HDAC1, HDAC2 and HDAC3; the
CC       interactions are not dependent on the APEX1 acetylation status.
CC       Interacts with XRCC1; the interaction is induced by SIRT1 and increased
CC       with the APEX1 acetylated form. Interacts with NPM1 (via N-terminal
CC       domain); the interaction is RNA-dependent and decreases in hydrogen
CC       peroxide-damaged cells. Interacts (via N-terminus) with YBX1 (via C-
CC       terminus); the interaction is increased in presence of APEX1 acetylated
CC       at Lys-6 and Lys-7. Interacts with HNRNPL; the interaction is DNA-
CC       dependent. Interacts (via N-terminus) with KPNA1 and KPNA2. Interacts
CC       with TXN; the interaction stimulates the FOS/JUN AP-1 complex DNA-
CC       binding activity in a redox-dependent manner. Interacts with GZMA,
CC       KRT8, MDM2, PRDX6, PRPF19, RPLP0, TOMM20 and WDR77. Interacts with POLB
CC       (PubMed:26760506, PubMed:9207062). Binds to CDK5.
CC       {ECO:0000269|PubMed:10667800, ECO:0000269|PubMed:11286553,
CC       ECO:0000269|PubMed:11809897, ECO:0000269|PubMed:11909973,
CC       ECO:0000269|PubMed:12524539, ECO:0000269|PubMed:14633989,
CC       ECO:0000269|PubMed:15942031, ECO:0000269|PubMed:18809583,
CC       ECO:0000269|PubMed:19188445, ECO:0000269|PubMed:19219073,
CC       ECO:0000269|PubMed:19934257, ECO:0000269|PubMed:20231292,
CC       ECO:0000269|PubMed:20699270, ECO:0000269|PubMed:26760506,
CC       ECO:0000269|PubMed:8621488, ECO:0000269|PubMed:9108029,
CC       ECO:0000269|PubMed:9207062, ECO:0000269|PubMed:9351835}.
CC   -!- INTERACTION:
CC       P27695; Q09472: EP300; NbExp=8; IntAct=EBI-1048805, EBI-447295;
CC       P27695; Q8N4N3: KLHL36; NbExp=2; IntAct=EBI-1048805, EBI-6426427;
CC       P27695; Q16236: NFE2L2; NbExp=3; IntAct=EBI-1048805, EBI-2007911;
CC       P27695; Q96EB6: SIRT1; NbExp=6; IntAct=EBI-1048805, EBI-1802965;
CC       P27695; O88846: Rnf4; Xeno; NbExp=2; IntAct=EBI-1048805, EBI-7258907;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00764}.
CC       Nucleus, nucleolus. Nucleus speckle. Endoplasmic reticulum. Cytoplasm.
CC       Note=Detected in the cytoplasm of B-cells stimulated to switch (By
CC       similarity). Colocalized with SIRT1 in the nucleus. Colocalized with
CC       YBX1 in nuclear speckles after genotoxic stress. Together with OGG1 is
CC       recruited to nuclear speckles in UVA-irradiated cells. Colocalized with
CC       nucleolin and NPM1 in the nucleolus. Its nucleolar localization is cell
CC       cycle dependent and requires active rRNA transcription. Colocalized
CC       with calreticulin in the endoplasmic reticulum. Translocation from the
CC       nucleus to the cytoplasm is stimulated in presence of nitric oxide (NO)
CC       and function in a CRM1-dependent manner, possibly as a consequence of
CC       demasking a nuclear export signal (amino acid position 64-80). S-
CC       nitrosylation at Cys-93 and Cys-310 regulates its nuclear-cytosolic
CC       shuttling. Ubiquitinated form is localized predominantly in the
CC       cytoplasm. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [DNA repair nuclease/redox regulator APEX1,
CC       mitochondrial]: Mitochondrion. Note=The cleaved APEX2 is only detected
CC       in mitochondria (By similarity). Translocation from the cytoplasm to
CC       the mitochondria is mediated by ROS signaling and cleavage mediated by
CC       granzyme A. Tom20-dependent translocated mitochondrial APEX1 level is
CC       significantly increased after genotoxic stress. {ECO:0000250}.
CC   -!- INDUCTION: Up-regulated in presence of reactive oxygen species (ROS),
CC       like bleomycin, H(2)O(2) and phenazine methosulfate.
CC       {ECO:0000269|PubMed:9560228}.
CC   -!- DOMAIN: The N-terminus contains the redox activity while the C-terminus
CC       exerts the DNA AP-endodeoxyribonuclease activity; both functions are
CC       independent in their actions. An unconventional mitochondrial targeting
CC       sequence (MTS) is harbored within the C-terminus, that appears to be
CC       masked by the N-terminal sequence containing the nuclear localization
CC       signal (NLS), that probably blocks the interaction between the MTS and
CC       Tom proteins.
CC   -!- PTM: Phosphorylated. Phosphorylation by kinase PKC or casein kinase CK2
CC       results in enhanced redox activity that stimulates binding of the
CC       FOS/JUN AP-1 complex to its cognate binding site. AP-
CC       endodeoxyribonuclease activity is not affected by CK2-mediated
CC       phosphorylation. Phosphorylation of Thr-233 by CDK5 reduces AP-
CC       endodeoxyribonuclease activity resulting in accumulation of DNA damage
CC       and contributing to neuronal death. {ECO:0000269|PubMed:10023679,
CC       ECO:0000269|PubMed:11452037}.
CC   -!- PTM: Acetylated on Lys-6 and Lys-7. Acetylation is increased by the
CC       transcriptional coactivator EP300 acetyltransferase, genotoxic agents
CC       like H(2)O(2) and methyl methanesulfonate (MMS). Acetylation increases
CC       its binding affinity to the negative calcium response element (nCaRE)
CC       DNA promoter. The acetylated form induces a stronger binding of YBX1 to
CC       the Y-box sequence in the MDR1 promoter than the unacetylated form.
CC       Deacetylated on lysines. Lys-6 and Lys-7 are deacetylated by SIRT1.
CC       {ECO:0000269|PubMed:14633989, ECO:0000269|PubMed:20699270}.
CC   -!- PTM: Cleaved at Lys-31 by granzyme A to create the mitochondrial form;
CC       leading to reduction of binding to DNA, AP endodeoxynuclease activity,
CC       redox activation of transcription factors and to enhanced cell death.
CC       Cleaved by granzyme K; leading to intracellular ROS accumulation and
CC       enhanced cell death after oxidative stress.
CC       {ECO:0000269|PubMed:12524539}.
CC   -!- PTM: Cys-65 and Cys-93 are nitrosylated in response to nitric oxide
CC       (NO) and lead to the exposure of the nuclear export signal (NES).
CC       {ECO:0000269|PubMed:17403694}.
CC   -!- PTM: Ubiquitinated by MDM2; leading to translocation to the cytoplasm
CC       and proteasomal degradation. {ECO:0000269|PubMed:19219073}.
CC   -!- MISCELLANEOUS: Extract of mitochondria, but not of nuclei or cytosol,
CC       cleaves recombinant APEX1 to generate a mitochondrial APEX1-sized
CC       product (By similarity). The specific activity of the cleaved
CC       mitochondrial endodeoxyribonuclease appears to be about 3-fold higher
CC       than that of the full-length form. {ECO:0000250|UniProtKB:P23196}.
CC   -!- SIMILARITY: Belongs to the DNA repair enzymes AP/ExoA family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X59764; CAA42437.1; -; mRNA.
DR   EMBL; M80261; AAA58371.1; -; mRNA.
DR   EMBL; D90373; BAA14381.1; -; mRNA.
DR   EMBL; S43127; AAB22977.1; -; mRNA.
DR   EMBL; M81955; AAA58372.1; -; mRNA.
DR   EMBL; M92444; AAA58629.1; -; Genomic_DNA.
DR   EMBL; X66133; CAA46925.1; -; Genomic_DNA.
DR   EMBL; D13370; BAA02633.1; -; Genomic_DNA.
DR   EMBL; U79268; AAB50212.1; -; mRNA.
DR   EMBL; BT007236; AAP35900.1; -; mRNA.
DR   EMBL; AF488551; AAL86909.1; -; Genomic_DNA.
DR   EMBL; AL355075; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002338; AAH02338.1; -; mRNA.
DR   EMBL; BC004979; AAH04979.1; -; mRNA.
DR   EMBL; BC008145; AAH08145.1; -; mRNA.
DR   EMBL; BC019291; AAH19291.1; -; mRNA.
DR   EMBL; M99703; AAA58373.1; -; Genomic_DNA.
DR   CCDS; CCDS9550.1; -.
DR   PIR; S23550; S23550.
DR   RefSeq; NP_001231178.1; NM_001244249.2.
DR   RefSeq; NP_001632.2; NM_001641.3.
DR   RefSeq; NP_542379.1; NM_080648.3.
DR   RefSeq; NP_542380.1; NM_080649.3.
DR   PDB; 1BIX; X-ray; 2.20 A; A=32-318.
DR   PDB; 1CQG; NMR; -; B=59-71.
DR   PDB; 1CQH; NMR; -; B=59-71.
DR   PDB; 1DE8; X-ray; 2.95 A; A/B=43-318.
DR   PDB; 1DE9; X-ray; 3.00 A; A/B=43-318.
DR   PDB; 1DEW; X-ray; 2.65 A; A/B=40-318.
DR   PDB; 1E9N; X-ray; 2.20 A; A/B=2-318.
DR   PDB; 1HD7; X-ray; 1.95 A; A=2-318.
DR   PDB; 2ISI; X-ray; 2.76 A; A/B/C=2-318.
DR   PDB; 2O3H; X-ray; 1.90 A; A=40-318.
DR   PDB; 3U8U; X-ray; 2.15 A; A/B/C/D/E/F=1-318.
DR   PDB; 4IEM; X-ray; 2.39 A; A/B/C/D=2-318.
DR   PDB; 4LND; X-ray; 1.92 A; A/B/C=39-318.
DR   PDB; 4QH9; X-ray; 2.18 A; A=38-318.
DR   PDB; 4QHD; X-ray; 1.65 A; A=38-318.
DR   PDB; 4QHE; X-ray; 1.40 A; A=38-318.
DR   PDB; 5CFG; X-ray; 1.80 A; A=44-318.
DR   PDB; 5DFF; X-ray; 1.57 A; A/B=43-318.
DR   PDB; 5DFH; X-ray; 1.95 A; A/B=43-318.
DR   PDB; 5DFI; X-ray; 1.63 A; A/B=43-318.
DR   PDB; 5DFJ; X-ray; 1.85 A; A/B=43-318.
DR   PDB; 5DG0; X-ray; 1.80 A; A/B=43-318.
DR   PDB; 5WN0; X-ray; 2.60 A; A/B=43-318.
DR   PDB; 5WN1; X-ray; 2.30 A; A/B=43-318.
DR   PDB; 5WN2; X-ray; 2.29 A; A/B=43-318.
DR   PDB; 5WN3; X-ray; 2.00 A; A/B=43-318.
DR   PDB; 5WN4; X-ray; 2.10 A; A/B=43-318.
DR   PDB; 5WN5; X-ray; 2.20 A; A/B=43-318.
DR   PDB; 6BOQ; X-ray; 1.96 A; A/B=1-318.
DR   PDB; 6BOR; X-ray; 1.84 A; A/B=1-318.
DR   PDB; 6BOS; X-ray; 2.30 A; A/B=1-318.
DR   PDB; 6BOT; X-ray; 2.30 A; A/B=1-318.
DR   PDB; 6BOU; X-ray; 2.54 A; A/B=1-318.
DR   PDB; 6BOV; X-ray; 1.98 A; A/B=1-318.
DR   PDB; 6BOW; X-ray; 1.59 A; A/B=1-318.
DR   PDB; 6MK3; X-ray; 1.48 A; A=40-318.
DR   PDB; 6MKK; X-ray; 1.44 A; A=40-318.
DR   PDB; 6MKM; X-ray; 1.67 A; A=40-318.
DR   PDB; 6MKO; X-ray; 2.09 A; A=40-318.
DR   PDB; 6P93; X-ray; 2.10 A; A/B=43-318.
DR   PDB; 6P94; X-ray; 2.09 A; A/B=43-318.
DR   PDB; 6W0Q; X-ray; 1.89 A; A/B=43-318.
DR   PDB; 6W2P; X-ray; 1.94 A; A/B=43-318.
DR   PDB; 6W3L; X-ray; 2.59 A; A/B=43-318.
DR   PDB; 6W3N; X-ray; 2.69 A; A/B=43-318.
DR   PDB; 6W3Q; X-ray; 2.49 A; A/B=43-318.
DR   PDB; 6W3U; X-ray; 2.40 A; A/B=43-318.
DR   PDB; 6W43; X-ray; 1.99 A; A/B=43-318.
DR   PDB; 6W4I; X-ray; 2.20 A; A/B=43-318.
DR   PDB; 6W4T; X-ray; 2.77 A; A/B=43-318.
DR   PDB; 7LPG; X-ray; 2.08 A; B/D=43-318.
DR   PDB; 7LPH; X-ray; 1.99 A; B/D=43-318.
DR   PDB; 7LPI; X-ray; 2.05 A; B/D=43-318.
DR   PDB; 7LPJ; X-ray; 2.56 A; B/D=43-318.
DR   PDB; 7MCR; X-ray; 1.90 A; A=44-318.
DR   PDB; 7MEV; X-ray; 1.60 A; A=44-318.
DR   PDB; 7SUV; X-ray; 1.99 A; A/B=43-318.
DR   PDB; 7SVB; X-ray; 2.24 A; A/B=43-318.
DR   PDB; 7TC2; X-ray; 1.43 A; A/B/C/D=39-318.
DR   PDB; 7TC3; X-ray; 1.25 A; A=39-318.
DR   PDB; 7TR7; X-ray; 2.00 A; A/B=43-318.
DR   PDB; 7U50; EM; 3.40 A; K=1-318.
DR   PDB; 9DP1; X-ray; 2.29 A; A/B=43-318.
DR   PDB; 9DP2; X-ray; 1.99 A; A/B=43-318.
DR   PDB; 9DP3; X-ray; 2.10 A; A/B=43-318.
DR   PDB; 9DP4; X-ray; 2.25 A; A/B=43-318.
DR   PDBsum; 1BIX; -.
DR   PDBsum; 1CQG; -.
DR   PDBsum; 1CQH; -.
DR   PDBsum; 1DE8; -.
DR   PDBsum; 1DE9; -.
DR   PDBsum; 1DEW; -.
DR   PDBsum; 1E9N; -.
DR   PDBsum; 1HD7; -.
DR   PDBsum; 2ISI; -.
DR   PDBsum; 2O3H; -.
DR   PDBsum; 3U8U; -.
DR   PDBsum; 4IEM; -.
DR   PDBsum; 4LND; -.
DR   PDBsum; 4QH9; -.
DR   PDBsum; 4QHD; -.
DR   PDBsum; 4QHE; -.
DR   PDBsum; 5CFG; -.
DR   PDBsum; 5DFF; -.
DR   PDBsum; 5DFH; -.
DR   PDBsum; 5DFI; -.
DR   PDBsum; 5DFJ; -.
DR   PDBsum; 5DG0; -.
DR   PDBsum; 5WN0; -.
DR   PDBsum; 5WN1; -.
DR   PDBsum; 5WN2; -.
DR   PDBsum; 5WN3; -.
DR   PDBsum; 5WN4; -.
DR   PDBsum; 5WN5; -.
DR   PDBsum; 6BOQ; -.
DR   PDBsum; 6BOR; -.
DR   PDBsum; 6BOS; -.
DR   PDBsum; 6BOT; -.
DR   PDBsum; 6BOU; -.
DR   PDBsum; 6BOV; -.
DR   PDBsum; 6BOW; -.
DR   PDBsum; 6MK3; -.
DR   PDBsum; 6MKK; -.
DR   PDBsum; 6MKM; -.
DR   PDBsum; 6MKO; -.
DR   PDBsum; 6P93; -.
DR   PDBsum; 6P94; -.
DR   PDBsum; 6W0Q; -.
DR   PDBsum; 6W2P; -.
DR   PDBsum; 6W3L; -.
DR   PDBsum; 6W3N; -.
DR   PDBsum; 6W3Q; -.
DR   PDBsum; 6W3U; -.
DR   PDBsum; 6W43; -.
DR   PDBsum; 6W4I; -.
DR   PDBsum; 6W4T; -.
DR   PDBsum; 7LPG; -.
DR   PDBsum; 7LPH; -.
DR   PDBsum; 7LPI; -.
DR   PDBsum; 7LPJ; -.
DR   PDBsum; 7MCR; -.
DR   PDBsum; 7MEV; -.
DR   PDBsum; 7SUV; -.
DR   PDBsum; 7SVB; -.
DR   PDBsum; 7TC2; -.
DR   PDBsum; 7TC3; -.
DR   PDBsum; 7TR7; -.
DR   PDBsum; 7U50; -.
DR   PDBsum; 9DP1; -.
DR   PDBsum; 9DP2; -.
DR   PDBsum; 9DP3; -.
DR   PDBsum; 9DP4; -.
DR   AlphaFoldDB; P27695; -.
DR   BMRB; P27695; -.
DR   EMDB; EMD-26336; -.
DR   SMR; P27695; -.
DR   BioGRID; 106825; 1270.
DR   CORUM; P27695; -.
DR   DIP; DIP-6130N; -.
DR   FunCoup; P27695; 2231.
DR   IntAct; P27695; 61.
DR   MINT; P27695; -.
DR   STRING; 9606.ENSP00000216714; -.
DR   BindingDB; P27695; -.
DR   ChEMBL; CHEMBL5619; -.
DR   DrugBank; DB18786; APX-3330.
DR   DrugBank; DB04967; Lucanthone.
DR   DrugCentral; P27695; -.
DR   MoonProt; P27695; -.
DR   GlyCosmos; P27695; 1 site, 2 glycans.
DR   GlyGen; P27695; 3 sites, 2 O-linked glycans (1 site).
DR   iPTMnet; P27695; -.
DR   MetOSite; P27695; -.
DR   PhosphoSitePlus; P27695; -.
DR   SwissPalm; P27695; -.
DR   BioMuta; APEX1; -.
DR   DMDM; 113984; -.
DR   CPTAC; CPTAC-23; -.
DR   CPTAC; CPTAC-24; -.
DR   jPOST; P27695; -.
DR   MassIVE; P27695; -.
DR   PaxDb; 9606-ENSP00000216714; -.
DR   PeptideAtlas; P27695; -.
DR   ProteomicsDB; 54406; -.
DR   Pumba; P27695; -.
DR   TopDownProteomics; P27695; -.
DR   Antibodypedia; 62; 947 antibodies from 46 providers.
DR   CPTC; P27695; 1 antibody.
DR   DNASU; 328; -.
DR   Ensembl; ENST00000216714.8; ENSP00000216714.3; ENSG00000100823.12.
DR   Ensembl; ENST00000398030.8; ENSP00000381111.4; ENSG00000100823.12.
DR   Ensembl; ENST00000555414.5; ENSP00000451979.1; ENSG00000100823.12.
DR   Ensembl; ENST00000708787.1; ENSP00000517339.1; ENSG00000291796.1.
DR   Ensembl; ENST00000708794.1; ENSP00000517342.1; ENSG00000291796.1.
DR   Ensembl; ENST00000708795.1; ENSP00000517343.1; ENSG00000291796.1.
DR   GeneID; 328; -.
DR   KEGG; hsa:328; -.
DR   MANE-Select; ENST00000216714.8; ENSP00000216714.3; NM_001641.4; NP_001632.2.
DR   UCSC; uc058yte.1; human.
DR   AGR; HGNC:587; -.
DR   CTD; 328; -.
DR   DisGeNET; 328; -.
DR   GeneCards; APEX1; -.
DR   HGNC; HGNC:587; APEX1.
DR   HPA; ENSG00000100823; Low tissue specificity.
DR   MIM; 107748; gene.
DR   OpenTargets; ENSG00000100823; -.
DR   VEuPathDB; HostDB:ENSG00000100823; -.
DR   eggNOG; KOG1294; Eukaryota.
DR   GeneTree; ENSGT00530000063540; -.
DR   HOGENOM; CLU_027539_1_3_1; -.
DR   InParanoid; P27695; -.
DR   OMA; WWSYRGR; -.
DR   OrthoDB; 498125at2759; -.
DR   PAN-GO; P27695; 5 GO annotations based on evolutionary models.
DR   PhylomeDB; P27695; -.
DR   BRENDA; 4.2.99.18; 2681.
DR   PathwayCommons; P27695; -.
DR   Reactome; R-HSA-110357; Displacement of DNA glycosylase by APEX1.
DR   Reactome; R-HSA-110362; POLB-Dependent Long Patch Base Excision Repair.
DR   Reactome; R-HSA-110373; Resolution of AP sites via the multiple-nucleotide patch replacement pathway.
DR   Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair.
DR   Reactome; R-HSA-73930; Abasic sugar-phosphate removal via the single-nucleotide replacement pathway.
DR   Reactome; R-HSA-73933; Resolution of Abasic Sites (AP sites).
DR   SignaLink; P27695; -.
DR   SIGNOR; P27695; -.
DR   BioGRID-ORCS; 328; 22 hits in 1167 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   CD-CODE; DEE660B4; Stress granule.
DR   ChiTaRS; APEX1; human.
DR   EvolutionaryTrace; P27695; -.
DR   GeneWiki; APEX1; -.
DR   GenomeRNAi; 328; -.
DR   Pharos; P27695; Tchem.
DR   PRO; PR:P27695; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P27695; protein.
DR   Bgee; ENSG00000100823; Expressed in ganglionic eminence and 202 other cell types or tissues.
DR   ExpressionAtlas; P27695; baseline and differential.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0000781; C:chromosome, telomeric region; IC:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005840; C:ribosome; TAS:UniProtKB.
DR   GO; GO:0008408; F:3'-5' exonuclease activity; IDA:UniProtKB.
DR   GO; GO:0008296; F:3'-5'-DNA exonuclease activity; IDA:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0052720; F:class II DNA-(apurinic or apyrimidinic site) endonuclease activity; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0004520; F:DNA endonuclease activity; TAS:Reactome.
DR   GO; GO:0140431; F:DNA-(abasic site) binding; IMP:UniProtKB.
DR   GO; GO:0003906; F:DNA-(apurinic or apyrimidinic site) endonuclease activity; IDA:UniProtKB.
DR   GO; GO:0008311; F:double-stranded DNA 3'-5' DNA exonuclease activity; IBA:GO_Central.
DR   GO; GO:0008309; F:double-stranded DNA exodeoxyribonuclease activity; IDA:BHF-UCL.
DR   GO; GO:0003691; F:double-stranded telomeric DNA binding; IDA:BHF-UCL.
DR   GO; GO:0004519; F:endonuclease activity; IDA:MGI.
DR   GO; GO:0046872; F:metal ion binding; IDA:UniProtKB.
DR   GO; GO:0016491; F:oxidoreductase activity; IDA:UniProtKB.
DR   GO; GO:0090580; F:phosphodiesterase activity, acting on 3'-phosphoglycolate-terminated DNA strands; IDA:UniProtKB.
DR   GO; GO:0004528; F:phosphodiesterase I activity; TAS:UniProtKB.
DR   GO; GO:0008081; F:phosphoric diester hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; TAS:UniProtKB.
DR   GO; GO:0016890; F:site-specific endodeoxyribonuclease activity, specific for altered base; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; TAS:ProtInc.
DR   GO; GO:0004844; F:uracil DNA N-glycosylase activity; TAS:ProtInc.
DR   GO; GO:0006284; P:base-excision repair; IDA:CAFA.
DR   GO; GO:0006287; P:base-excision repair, gap-filling; TAS:Reactome.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:Ensembl.
DR   GO; GO:0006308; P:DNA catabolic process; IDA:UniProtKB.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0006281; P:DNA repair; IDA:UniProtKB.
DR   GO; GO:0044029; P:positive regulation of gene expression via chromosomal CpG island demethylation; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:ARUK-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; IMP:UniProtKB.
DR   GO; GO:0000723; P:telomere maintenance; IDA:BHF-UCL.
DR   GO; GO:0097698; P:telomere maintenance via base-excision repair; IDA:BHF-UCL.
DR   CDD; cd09087; Ape1-like_AP-endo; 1.
DR   DisProt; DP00007; -.
DR   FunFam; 3.60.10.10:FF:000009; DNA-(apurinic or apyrimidinic site) lyase; 1.
DR   Gene3D; 3.60.10.10; Endonuclease/exonuclease/phosphatase; 1.
DR   InterPro; IPR004808; AP_endonuc_1.
DR   InterPro; IPR020847; AP_endonuclease_F1_BS.
DR   InterPro; IPR020848; AP_endonuclease_F1_CS.
DR   InterPro; IPR036691; Endo/exonu/phosph_ase_sf.
DR   InterPro; IPR005135; Endo/exonuclease/phosphatase.
DR   NCBIfam; TIGR00195; exoDNase_III; 1.
DR   NCBIfam; TIGR00633; xth; 1.
DR   PANTHER; PTHR22748; AP ENDONUCLEASE; 1.
DR   PANTHER; PTHR22748:SF6; DNA-(APURINIC OR APYRIMIDINIC SITE) ENDONUCLEASE; 1.
DR   Pfam; PF03372; Exo_endo_phos; 1.
DR   SUPFAM; SSF56219; DNase I-like; 1.
DR   PROSITE; PS00726; AP_NUCLEASE_F1_1; 1.
DR   PROSITE; PS00727; AP_NUCLEASE_F1_2; 1.
DR   PROSITE; PS00728; AP_NUCLEASE_F1_3; 1.
DR   PROSITE; PS51435; AP_NUCLEASE_F1_4; 1.
DR   neXtProt; NX_P27695; -.
DR   PharmGKB; PA201059; -.
DR   TreeFam; TF315048; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Cleavage on pair of basic residues;
KW   Cytoplasm; Direct protein sequencing; Disulfide bond; DNA damage;
KW   DNA recombination; DNA repair; DNA-binding; Endonuclease;
KW   Endoplasmic reticulum; Exonuclease; Hydrolase; Magnesium; Metal-binding;
KW   Mitochondrion; Nuclease; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Repressor; RNA-binding;
KW   S-nitrosylation; Transcription; Transcription regulation; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12524539,
FT                   ECO:0000269|PubMed:1380454"
FT   CHAIN           2..318
FT                   /note="DNA repair nuclease/redox regulator APEX1"
FT                   /id="PRO_0000200010"
FT   CHAIN           32..318
FT                   /note="DNA repair nuclease/redox regulator APEX1,
FT                   mitochondrial"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000402572"
FT   REGION          1..60
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..33
FT                   /note="Necessary for interaction with YBX1, binding to RNA,
FT                   NPM1-dependent association with rRNA, endoribonuclease
FT                   activity on abasic RNA and localization in the nucleoli"
FT                   /evidence="ECO:0000269|PubMed:18809583"
FT   REGION          23..33
FT                   /note="Necessary for interaction with NPM1 and for
FT                   efficient rRNA binding"
FT   REGION          289..318
FT                   /note="Mitochondrial targeting sequence (MTS)"
FT   MOTIF           8..13
FT                   /note="Nuclear localization signal (NLS)"
FT   MOTIF           64..80
FT                   /note="Nuclear export signal (NES)"
FT   COMPBIAS        16..38
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        171
FT                   /evidence="ECO:0000269|PubMed:15380100"
FT   ACT_SITE        210
FT                   /note="Proton donor/acceptor"
FT                   /evidence="ECO:0000269|PubMed:9351835,
FT                   ECO:0007744|PDB:1BIX"
FT   ACT_SITE        309
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00764"
FT   BINDING         68
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00764"
FT   BINDING         96
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00764"
FT   BINDING         210
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00764"
FT   BINDING         212
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00764"
FT   BINDING         308
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00764"
FT   BINDING         309
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00764"
FT   SITE            31..32
FT                   /note="Cleavage; by granzyme A"
FT   SITE            212
FT                   /note="Transition state stabilizer"
FT                   /evidence="ECO:0000269|PubMed:8932375"
FT   SITE            283
FT                   /note="Important for catalytic activity"
FT                   /evidence="ECO:0000269|PubMed:21762700,
FT                   ECO:0000269|PubMed:9804799"
FT   SITE            309
FT                   /note="Interaction with DNA substrate"
FT   MOD_RES         6
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000269|PubMed:14633989"
FT   MOD_RES         7
FT                   /note="N6-acetyllysine; by EP300"
FT                   /evidence="ECO:0000269|PubMed:14633989"
FT   MOD_RES         27
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20699270"
FT   MOD_RES         31
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20699270"
FT   MOD_RES         32
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20699270"
FT   MOD_RES         35
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:20699270"
FT   MOD_RES         54
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         65
FT                   /note="S-nitrosocysteine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17403694"
FT   MOD_RES         93
FT                   /note="S-nitrosocysteine; alternate"
FT                   /evidence="ECO:0000269|PubMed:17403694"
FT   MOD_RES         197
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         233
FT                   /note="Phosphothreonine; by CDK5"
FT                   /evidence="ECO:0000250|UniProtKB:P28352"
FT   MOD_RES         310
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000269|PubMed:17403694"
FT   DISULFID        65..93
FT                   /note="Alternate"
FT                   /evidence="ECO:0000305"
FT   VARIANT         51
FT                   /note="Q -> H (in dbSNP:rs1048945)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_013455"
FT   VARIANT         64
FT                   /note="I -> V (in dbSNP:rs2307486)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_014823"
FT   VARIANT         148
FT                   /note="D -> E (in dbSNP:rs1130409)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.11"
FT                   /id="VAR_019790"
FT   MUTAGEN         6
FT                   /note="K->R: Lack of acetylation, does not stimulate the
FT                   YBX1-mediated MDR1 promoter activity and alter nuclear
FT                   subcellular localization; when associated with R-7. Does
FT                   not inhibit interaction with HDAC1, HDAC2 and HDAC3.
FT                   Absence of increase in nCaRE binding activity."
FT                   /evidence="ECO:0000269|PubMed:14633989,
FT                   ECO:0000269|PubMed:15942031, ECO:0000269|PubMed:18809583,
FT                   ECO:0000269|PubMed:19934257"
FT   MUTAGEN         7
FT                   /note="K->R: Lack of acetylation and does not stimulate the
FT                   YBX1-mediated MDR1 promoter activity and alter nuclear
FT                   subcellular localization; when associated with R-6."
FT                   /evidence="ECO:0000269|PubMed:14633989,
FT                   ECO:0000269|PubMed:15942031, ECO:0000269|PubMed:18809583,
FT                   ECO:0000269|PubMed:19934257"
FT   MUTAGEN         12
FT                   /note="E->A: Reduces nuclear localization; when associated
FT                   with A-13."
FT                   /evidence="ECO:0000269|PubMed:15942031"
FT   MUTAGEN         13
FT                   /note="D->A: Reduces nuclear localization; when associated
FT                   with A-12."
FT                   /evidence="ECO:0000269|PubMed:15942031"
FT   MUTAGEN         24
FT                   /note="K->A: Enhances the interaction with TOMM20. Inhibits
FT                   rRNA binding, interaction with NPM1, nuclear localization
FT                   and modulates its endodeoxyribonuclease activity; when
FT                   associated with A-25; A-27; A-31 and A-32. Inhibits
FT                   ubiquitination; when associated with K-25 and K-27."
FT                   /evidence="ECO:0000269|PubMed:19219073,
FT                   ECO:0000269|PubMed:20231292, ECO:0000269|PubMed:20699270"
FT   MUTAGEN         25
FT                   /note="K->A: Enhances the interaction with TOMM20. Inhibits
FT                   rRNA binding, interaction with NPM1, nuclear localization
FT                   and modulates its endodeoxyribonuclease activity; when
FT                   associated with A-24; A-27; A-31 and A-32. Inhibits
FT                   ubiquitination; when associated with K-24 and K-27."
FT                   /evidence="ECO:0000269|PubMed:19219073,
FT                   ECO:0000269|PubMed:20231292, ECO:0000269|PubMed:20699270"
FT   MUTAGEN         27
FT                   /note="K->A: Enhances the interaction with TOMM20. Inhibits
FT                   rRNA binding, interaction with NPM1, nuclear localization
FT                   and modulates its endodeoyribonuclease activity; when
FT                   associated with A-24; A-25; A-31 and A-32. Inhibits
FT                   ubiquitination; when associated with K-24 and K-25."
FT                   /evidence="ECO:0000269|PubMed:19219073,
FT                   ECO:0000269|PubMed:20231292, ECO:0000269|PubMed:20699270"
FT   MUTAGEN         31
FT                   /note="K->A: Enhances the interaction with TOMM20. Does not
FT                   inhibit redox and AP endodeoyribonuclease activities.
FT                   Inhibits rRNA binding, interaction with NPM1, nuclear
FT                   localization and modulates its endodeoxyribonuclease
FT                   activity; when associated with A-24; A-25; A-27 and A-32.
FT                   Reduces protection from granzyme A-mediated cell death;
FT                   when associated with A-65 and A-210."
FT                   /evidence="ECO:0000269|PubMed:12524539,
FT                   ECO:0000269|PubMed:20231292, ECO:0000269|PubMed:20699270"
FT   MUTAGEN         32
FT                   /note="K->A: Inhibits rRNA binding, interaction with NPM1,
FT                   nuclear localization and modulates its
FT                   endodeoxyribonuclease activity; when associated with A-24;
FT                   A-25; A-27 and A-31."
FT                   /evidence="ECO:0000269|PubMed:20699270"
FT   MUTAGEN         65
FT                   /note="C->A: Abolishes the redox activity. Does not abolish
FT                   the AP endodeoxyribonuclease and phosphodiesterase
FT                   activities. Reduces protection from granzyme A-mediated
FT                   cell death; when associated with A-31 and A-210."
FT                   /evidence="ECO:0000269|PubMed:12524539,
FT                   ECO:0000269|PubMed:18579163, ECO:0000269|PubMed:8355688"
FT   MUTAGEN         65
FT                   /note="C->S: Does not abolish NO-induced nitrosylation.
FT                   Enhances NO-induced nuclear export."
FT                   /evidence="ECO:0000269|PubMed:12524539,
FT                   ECO:0000269|PubMed:18579163, ECO:0000269|PubMed:8355688"
FT   MUTAGEN         68
FT                   /note="N->A: Nearly abolishes AP endodeoxyribonuclease
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:21762700"
FT   MUTAGEN         70
FT                   /note="D->A: Strongly reduces AP endodeoxyribonuclease
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:21762700"
FT   MUTAGEN         93
FT                   /note="C->A: Abolishes partially the redox activity."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   MUTAGEN         93
FT                   /note="C->S: Does not abolish NO-induced nitrosylation.
FT                   Abolishes NO-induced nitrosylation and translocation from
FT                   the nucleus to the cytoplasm; when associated with S-310."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   MUTAGEN         96
FT                   /note="E->A: Lacks MYCCRDRNA cleavage activity."
FT                   /evidence="ECO:0000269|PubMed:19401441"
FT   MUTAGEN         99
FT                   /note="C->A: Does not abolish the redox activity."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   MUTAGEN         138
FT                   /note="C->A: Does not abolish the redox activity."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   MUTAGEN         171
FT                   /note="Y->A,F,H: Abolishes the AP endodeoxyribonuclease
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:15380100,
FT                   ECO:0000269|PubMed:21762700"
FT   MUTAGEN         208
FT                   /note="C->A: Does not abolish the redox activity."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   MUTAGEN         210
FT                   /note="D->A,N: Abolishes the AP endodeoxyribonuclease
FT                   activity. Reduces protection from granzyme A-mediated cell
FT                   death; when associated with A-31 and A-65."
FT                   /evidence="ECO:0000269|PubMed:12524539"
FT   MUTAGEN         212
FT                   /note="N->A: Abolishes AP endodeoxyribonuclease activity."
FT                   /evidence="ECO:0000269|PubMed:8932375"
FT   MUTAGEN         212
FT                   /note="N->Q,D: Decreases AP endodeoxyribonuclease
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:8932375"
FT   MUTAGEN         266
FT                   /note="F->A: Strongly reduces AP endodeoxyribonuclease
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:21762700"
FT   MUTAGEN         283
FT                   /note="D->A: Strongly reduces AP endodeoxyribonuclease
FT                   activity, but does not affect RNA cleavage activity. Nearly
FT                   abolishes AP endodeoxyribonuclease activity; when
FT                   associated with A-308."
FT                   /evidence="ECO:0000269|PubMed:21762700,
FT                   ECO:0000269|PubMed:9804799"
FT   MUTAGEN         296
FT                   /note="C->A: Does not abolish the redox activity."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   MUTAGEN         299
FT                   /note="K->A: Reduces the interaction with TOMM20. Abolishes
FT                   localization in the mitochondria; when associated with
FT                   A-301."
FT                   /evidence="ECO:0000269|PubMed:20231292"
FT   MUTAGEN         301
FT                   /note="R->A: Reduces the interaction with TOMM20. Abolishes
FT                   localization in the mitochondria; when associated with
FT                   A-299."
FT                   /evidence="ECO:0000269|PubMed:20231292"
FT   MUTAGEN         303
FT                   /note="K->A: Reduces the interaction with TOMM20."
FT                   /evidence="ECO:0000269|PubMed:20231292"
FT   MUTAGEN         308
FT                   /note="D->A: Reduces AP endodeoxyribonuclease activity.
FT                   Nearly abolishes AP endodeoxyribonuclease activity; when
FT                   associated with A-283."
FT                   /evidence="ECO:0000269|PubMed:21762700,
FT                   ECO:0000269|PubMed:9804799"
FT   MUTAGEN         309
FT                   /note="H->N,S: Abolishes AP endodeoxyribonuclease activity.
FT                   Lacks MYCCRDRNA cleavage activity."
FT                   /evidence="ECO:0000269|PubMed:19401441,
FT                   ECO:0000269|PubMed:21762700, ECO:0000269|PubMed:9804799"
FT   MUTAGEN         310
FT                   /note="C->A: Does not abolish the redox activity."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   MUTAGEN         310
FT                   /note="C->S: Does not abolish NO-induced nitrosylation.
FT                   Abolishes NO-induced nitrosylation and translocation from
FT                   the nucleus to the cytoplasm; when associated with S-93."
FT                   /evidence="ECO:0000269|PubMed:18579163,
FT                   ECO:0000269|PubMed:8355688"
FT   CONFLICT        57
FT                   /note="G -> A (in Ref. 2; AAA58371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        306
FT                   /note="G -> A (in Ref. 2; AAA58371)"
FT                   /evidence="ECO:0000305"
FT   STRAND          62..68
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           72..77
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           80..87
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          90..95
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           101..103
FT                   /evidence="ECO:0007829|PDB:5DFF"
FT   HELIX           106..110
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           112..114
FT                   /evidence="ECO:0007829|PDB:4QHE"
FT   STRAND          116..120
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          122..124
FT                   /evidence="ECO:0007829|PDB:7MEV"
FT   STRAND          127..129
FT                   /evidence="ECO:0007829|PDB:4QHE"
FT   STRAND          131..137
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          140..145
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           149..151
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          152..155
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          157..161
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          166..171
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           182..200
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          205..210
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           217..219
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   TURN            224..228
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   TURN            230..232
FT                   /evidence="ECO:0007829|PDB:7LPI"
FT   HELIX           234..246
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:7MCR"
FT   HELIX           252..256
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          257..259
FT                   /evidence="ECO:0007829|PDB:1DE9"
FT   STRAND          265..267
FT                   /evidence="ECO:0007829|PDB:7U50"
FT   HELIX           270..272
FT                   /evidence="ECO:0007829|PDB:6BOW"
FT   HELIX           273..276
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          283..287
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   HELIX           289..294
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          295..300
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          306..309
FT                   /evidence="ECO:0007829|PDB:7TC3"
FT   STRAND          312..316
FT                   /evidence="ECO:0007829|PDB:7TC3"
SQ   SEQUENCE   318 AA;  35555 MW;  B88579C01BAF80C6 CRC64;
     MPKRGKKGAV AEDGDELRTE PEAKKSKTAA KKNDKEAAGE GPALYEDPPD QKTSPSGKPA
     TLKICSWNVD GLRAWIKKKG LDWVKEEAPD ILCLQETKCS ENKLPAELQE LPGLSHQYWS
     APSDKEGYSG VGLLSRQCPL KVSYGIGDEE HDQEGRVIVA EFDSFVLVTA YVPNAGRGLV
     RLEYRQRWDE AFRKFLKGLA SRKPLVLCGD LNVAHEEIDL RNPKGNKKNA GFTPQERQGF
     GELLQAVPLA DSFRHLYPNT PYAYTFWTYM MNARSKNVGW RLDYFLLSHS LLPALCDSKI
     RSKALGSDHC PITLYLAL
//
